Scalable & Flexible Bioprocess Solutions - For TB Vaccine Making

Tuberculosis (TB) is a communicable, bacterial illness affecting the lungs that has crippled humanity for many years and is still counted as one of the deadliest contagious diseases affecting more than a million people globally every year. Caused by Mycobacterium tuberculosis, the disease spreads through patients’ coughs and sneezes and affects mainly the lungs, spine, and brain. Tuberculosis infection can be classified into primary tuberculosis, latent tuberculosis, active tuberculosis, and active tuberculosis outside the lungs and is characterized by long-lasting cough, chest pain, consistent tiredness, night sweats, chills, fever, etc. ?Host biomarkers (relying on serum, plasma, stimulated or unstimulated blood and plasma) and pathogen-related biomarkers (from urine and blood) play a crucial role in diagnosing TB diagnosis. The extensive treatment phase and continuation phase make one think prevention of the disease is a safer option than cure after contracting the disease. Based on the platform used, the tuberculosis vaccine can be a mycobacterial killed, whole-cell, or extract vaccine, live-attenuated mycobacterial vaccine, recombinant live-attenuated or replication-deficient virus-vectored or a mycobacterial fusion protein in an adjuvant formulation. Though over 15 vaccine candidates are progressing through clinical trials to prevent infection and recurrence of tuberculosis, BCG, a live, attenuated vaccine is the only approved vaccine for tuberculosis to date.

To reduce incidences of tuberculosis in the modern world, the discovery of a novel, more protective, efficacious, and sustainable vaccine that provides a comprehensive immune response is undisputed.?The development of novel tuberculosis vaccines continues to face many challenges such as lack of clear defensive antigens, lack of reliable preclinical evaluation indicators, lack of satisfactory vaccine evaluation model, dearth of reproducible exposure methods, shortage of clinical trial endpoint criteria, lack of consistent evaluation environment and complicated, diverse immunization population.?Tuberculosis vaccines should be able to provide protective efficacy, stability, and long-lasting immunogenicity with no adverse reactions.

DDE with its 4 decades of biopharma industry experience would like to collaborate with innovators in the development of a safe, broad spectrum, durable, interference-hardy, compatible, sturdy, and cost-effective TB vaccine that will impede this life-threatening disease by single or several immunizations. We enable scalable and flexible bioprocess solutions combining the optimal manufacturing procedure with omics approaches, that allow us to achieve the ultimate goal of developing an effective and promising vaccine and constructing a tuberculosis-free world.

#StopTB #EndTuberculosis #TBVaccine #HealthcareInnovation

#PublicHealth #Biopharma #VaccineDevelopment #ClinicalTrials

#DDEBiopharma #Collaboration #OmicsApproaches #TuberculosisFreeWorld

TuBerculosis Vaccine Initiative (TBVI) International Union Against Tuberculosis and Lung Disease (The Union) National Tuberculosis, Leprosy and Lung Disease Program Friends of the Global Fight Against AIDS, Tuberculosis and Malaria Inspi Tuberculosis Tuberculosis Serology in NHP TUBERCULOSIS L. South African Tuberculosis Vaccine Initiative (SATVI)